IN52: GICAMI (Internal Medicine Clinical Assistance Research Group)

Group dedicated to clinical epidemiological research on the most frequent pathologies in the field of Internal Medicine, such as polypathological patients, heart failure, cardiovascular risk factors and autoimmune pathologies.

• Cardiovascular Risk Factors (Dr Patricia Rubio Marín) will be in charge of carrying out studies on type 2 DM, HBP and Familial Hypercholesterolemia among others. Investigation of genetics and risk factors associated with HFH, early diagnosis.
• Polypathological Patients and Heart Failure (Dra Eva Lozano Loaiza) our group presents a registry of polypathological patients under follow-up in our unit.
• Pulmonary Hypertension (Dr. Josefa Jimenez Arjona), research within the Pulmonary Hypertension unit of HUJ on group 1 pulmonary artery hypertension, use of IST2 as a prognostic marker in PAH.

Polypathology Cardiovascular risk Diabetes Familial hypercholesterolemia Heart failure Pulmonary hypertension

• Principal Investigators:
  • Patricia Rubio Marín (PI).
  • Eva Lozano Loaíza (Co-PI).
• Investigators:
  • Virginia Naranjo Velasco.
  • Gloria Pérez Vázquez.
  • Carmen Bocanegra Muñoz.
  • Juan Mora Delgado.
  • Cristina Lojo Cruz.
  • Elisa Barroso Casamitjana.
  • Eva Menor Campos.
  • Carolina García Figueras Mateos.
  • Salvadora Diosdado Nuñez.
  • Angela Cabrera de la Calle.
  • Catalina Becerra Pérez.
• Postdoctoral Researchers:
  • Josefa Jiménez Arjona.

1. RodrigoAlonsoMD, PhDabOvidioMuñiz-GrijalvoMD, PhDcJose LuisDíaz-DíazMD, PhDdDanielZambónMD, PhDeRaimundode AndrésMD, PhDfRaquelArroyo-OlivaresaFranciscoFuentes-JimenezMD, PhDgJuan SanchezMuñoz-TorreroMD, PhDhJoseCepedaMD, PhDiRocíoAguadoMD, PhDjPilarAlvarez-BañosMDkMartaCasañasMDlMartaDieguezMDmMaría DoloresMañasMDnPatriciaRubioMD. PhDoRosaArguesoMD, PhDpFranciscoArrietaMD, PhDqPabloGonzalez-BustosMDr…PedroMataMD, PhDa. Efficacy of PCSK9 inhibitors in the treatment of heterozygous familial hypercholesterolemia: A clinical practice experience Journal of clinical lipidology (2021) 000 1-9.

1. Patricia Rubio-Marín,Alfredo Michán-Doña,Juan Maraver-Delgado, Raquel Arroyo-Olivares Rosalía Barrado Varea, Leopoldo Pérez de Isla,Pedro Mata. Cascade screening program for familial hypercholesterolemia. Endocrinol Diabetes Nutr. 2018 May;65(5):280-286. Doi: 10.1016/j.endinu.2017.12.009. FI:0,33 Q3.

1. Pérez de Isla L, Alonso R, Mata N, Saltijeral A, Muñiz O,Rubio-Marin P, Diaz-Diaz JL, Fuentes F, de Andrés R, Zambón D, Galiana J, Piedecausa M, Aguado R, Mosquera D, Vidal JI, Ruiz E, Manjón L, Mauri M, Padró T, Miramontes JP, Mata P; SAFEHEART Investigators. Coronary Heart Disease, Peripheral Arterial Disease, and Stroke in Familial Hypercholesterolaemia: Insights From the SAFEHEART Registry (Spanish Familial Hypercholesterolaemia Cohort Study). Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):2004-10. doi: 10.1161/ATVBAHA.116.307514. Epub 2016 Jul 21.
2. Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P; SAFEHEART Investigators. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.

• Premio a la mejor publicación del año 2017 otorgado por la Sociedad Española de Cardiología. Perez de Isla L, Alonso R, Watts GF, Mata N, Saltijeral Cerezo A, Muñiz O, Fuentes F, Diaz-Diaz JL, de Andrés R, Zambón D, Rubio-Marin P, Barba-Romero MA, Saenz P, Sanchez Muñoz-Torrero JF, Martinez-Faedo C, Miramontes-Gonzalez JP, Badimón L, Mata P; SAFEHEART Investigators. Attainment of LDL-Cholesterol Treatment Goals in Patients With Familial Hypercholesterolemia: 5-Year SAFEHEART Registry Follow-Up. J Am Coll Cardiol. 2016 Mar 22;67(11):1278-85. doi: 10.1016/j.jacc.2016.01.008.